Health committee  We're piloting the model right now. We have a lot of interest for doing it again in other places.

Health committee  Exactly. We're decoupling the research and development costs from the marketing and distribution costs.

Health committee  There would be a licensing agreement. We would be licensing the regulatory data and the regulatory approval, if it went that late in the development process.

Health committee  That's a real, tangible asset. It gives you an entitlement to protection from generic competition. In Canada, for example, we have innovative drug status for new chemical entities that come to market. That gives you eight years when you have sole market protection. That's a real,

Health committee  I'll give you a little background on M4K Pharma. Our company, as in the Newman foundation scenario, is wholly owned by a charity. You could conceive of scenarios in which you attract impact investors who are willing to balance returns with other socially minded objectives when th